The bill amends section 9 of the Small Business Act to prolong and widen temporary SBIR/STTR authorities through fiscal year 2030. It converts the existing limited direct-to-Phase II pilot into a standing option available to all federal agencies required to run an SBIR program, while also adding statutory limits on how much of an agency’s SBIR budget may be used for direct-to-Phase II awards.
In addition to the direct-to-Phase II changes, the measure renames and extends the civilian-agency commercialization readiness authority and extends two other SBIR/STTR pilot programs — a Phase 0 proof-of-concept partnership and commercialization assistance pilots — through September 30, 2030. The bill also adds a reporting requirement for agencies that use the expanded authority.
At a Glance
What It Does
The bill extends the temporary authority that lets agencies award Phase II SBIR/STTR funds without a Phase I award, opens that authority to every federal agency required to run an SBIR program, and caps the share of an agency’s SBIR budget that may go to those awards (10% generally, 15% for NIH). It also pushes multiple commercialization-focused pilots and programs out to FY2030 and changes program labels from "pilot" to "covered program" for certain civilian efforts.
Who It Affects
Affected parties include federal agencies that operate SBIR/STTR programs (notably NIH, DOD, DOE and others), small businesses that apply for SBIR/STTR awards, and agency program managers responsible for award design and budget allocation. Intermediaries that provide commercialization assistance and entities running Phase 0 partnerships also see their pilot windows extended.
Why It Matters
The changes institutionalize a faster route to Phase II for eligible projects while putting statutory budgetary limits around that route, which reshapes how agencies manage their SBIR portfolios. For program managers and compliance officers, the bill creates new allocation and reporting obligations; for small businesses it alters pathways to follow-on funding and commercialization support.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The central change is widening and extending the authority that lets agencies skip Phase I and move a project directly to Phase II funding. Where previously that option was limited to a few named agencies and a set timeframe, the bill substitutes a broader formulation so every federal agency that must run an SBIR program can use the authority through fiscal year 2030.
To prevent wholesale diversion of funds away from Phase I work, the bill pairs the expanded authority with numeric ceilings: an agency may not spend more than 10 percent of its SBIR allocation on direct-to-Phase II awards in a fiscal year, and NIH may spend up to 15 percent.
Practically, agencies that choose to use the authority will need to change internal guidance, solicitation language, and accounting practices so direct-to-Phase II awards are tracked separately and counted toward the specified percentage limits. The statute also requires each agency head who uses the authority to disclose the number and dollar value of such awards in the agency’s next report submitted under the statute’s reporting clause (g)(9), creating a discrete transparency hook for oversight.Beyond direct-to-Phase II, the bill adjusts program labels and extends multiple pilot programs.
It converts a civilian-focused commercialization pilot heading to "Civilian Agencies Commercialization Readiness," replaces references to "pilot program" with "covered program," and extends the expiration dates for a Phase 0 proof-of-concept partnership program and commercialization assistance pilots to September 30, 2030. Those date changes preserve experimental commercialization tools and give agencies and external partners more time to pilot support models intended to bridge lab results toward market-ready products.Taken together, the amendments speed a path for mature technologies to reach Phase II funding and extend commercialization experiments, but they do so within new statutory bounds and reporting lines that agencies must operationalize.
That will alter solicitation design, prioritization decisions, and internal budgeting for SBIR/STTR portfolios over the next five years.
The Five Things You Need to Know
The bill extends the temporary direct-to-Phase II authority in section 9(cc) of the Small Business Act through fiscal year 2030 by amending subsection (cc).
It expands eligibility so that "each Federal agency required to carry out an SBIR program" — not just NIH, DOD, and the Department of Education — may use direct-to-Phase II awards.
It imposes statutory spending limits on direct-to-Phase II awards: no more than 10% of an agency’s SBIR funds in a fiscal year, except NIH is allowed up to 15%.
The bill requires any agency that uses the direct-to-Phase II authority to report the number and dollar amount of such awards in the next report submitted under subsection (g)(9).
It extends three commercialization-related pilots/programs to September 30, 2030: the Phase 0 proof-of-concept partnership (section 9(jj)(7)), commercialization assistance pilots (section 9(uu)(3)), and the civilian agencies commercialization readiness authority (section 9(gg)).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the bill as the "SBIR/STTR Pilot Extension Act." This is a purely captioning provision but signals the bill’s intent to extend existing temporary authorities tied to SBIR/STTR commercialization experimentation.
Extend and expand direct-to-Phase II; add limits and reporting
This is the operative change to the phase flexibility authority. It first reorganizes the existing text by designating the current subsection as a paragraph and then replaces the agency-specific grant of authority with a universal formulation allowing any federal agency required to operate an SBIR program to award direct-to-Phase II funds. It inserts two checks: a cap that normally limits such awards to 10 percent of an agency’s SBIR allocation and a 15 percent cap for NIH. Finally, it adds a reporting obligation that ties the disclosure of usage (number and amounts of awards) to the agency’s next report under subsection (g)(9). For administrators, the provision creates an affirmative duty to budget, track, and publicly account for direct-to-Phase II spending, and for counsel and compliance officers it creates a discrete statutory metric to audit.
Rename and extend civilian commercialization readiness authority
This amendment changes the heading from "Pilot" to "Civilian Agencies Commercialization Readiness," replaces the phrase "pilot program" with "covered program," and extends the expiration date from fiscal year 2025 to fiscal year 2030. The textual changes are modest but meaningful: renaming and swapping the terminology signals a move from an experimental posture toward a more sustained program for civilian agencies, and the five-year extension gives agencies additional runway to test and scale commercialization-readiness interventions.
Extend Phase 0 proof-of-concept partnership program
Updates the statutory end date for the Phase 0 proof-of-concept partnership program to September 30, 2030. That maintains the Phase 0 pathway — which supports early-stage concept validation in partnership with external organizations — for another five-year span, allowing continued testing of pre-Phase I support structures.
Extend commercialization assistance pilot programs
Moves the expiration date for commercialization assistance pilots to September 30, 2030. Extending these pilots preserves authorities for agencies to provide or fund commercialization support services (mentoring, market validation, investor engagement) while agencies collect more evidence about effective models.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Small businesses with late-stage R&D: Firms that have passed proof-of-concept elsewhere can access Phase II funds faster under direct-to-Phase II, shortening the time to larger follow-on awards and commercialization support.
- NIH-funded biomedical projects: NIH receives a higher statutory ceiling (15%) than other agencies, giving biomedical projects comparatively greater flexibility to move directly to Phase II where appropriate.
- Program offices and commercialization intermediaries: Agencies and third-party intermediaries running commercialization assistance or Phase 0 partnerships get a five-year extension to iterate and scale pilot models without immediate sunset pressure.
- Investors and product developers: A faster route to Phase II can make SBIR/STTR-funded technologies more investment-ready sooner, improving private-sector engagement opportunities.
- Agencies seeking portfolio flexibility: Smaller or mission-specific agencies that previously lacked the authority can now use direct-to-Phase II to pursue mature proposals aligned with agency priorities.
Who Bears the Cost
- SBIR/STTR program budgets and Phase I applicants: Direct-to-Phase II awards draw from the same statutory pool, meaning some funds that would otherwise go to Phase I competitions may be reallocated, potentially reducing Phase I opportunities.
- Agency program managers and finance staff: Agencies must implement tracking, adjust solicitations and merit review procedures, and enforce percentage ceilings, increasing administrative workload and requiring new internal controls.
- Congressional and agency oversight functions: The added reporting creates oversight duties for Congress and watchdog offices, which must review compliance with caps and program use.
- Small agencies with limited SBIR budgets: Agencies with smaller SBIR allocations face tighter choices since a 10% cap may still represent a material portion of their budget and could constrain other activities.
- External commercialization service providers: If agencies change the mix of Phase I vs Phase II awards, demand for certain early-stage assistance services could fall, forcing intermediaries to adapt their business models.
Key Issues
The Core Tension
The bill's central dilemma is a classic trade-off between accelerating commercialization for mature technologies and preserving the role of Phase I as a proof-of-concept and broadening instrument: giving agencies more discretion to award direct-to-Phase II speeds capital to promising projects but risks diverting scarce set-aside funds away from early-stage validation and from a broader base of small innovators; the statutory caps and reporting try to mediate that conflict but leave key definitional and implementation choices unresolved.
Two implementation headaches stand out. First, the caps are easy to state but operationally messy: agencies will need reliable, contemporaneous accounting to ensure cumulative direct-to-Phase II awards do not exceed 10 percent (or 15 percent for NIH) of their annual SBIR allotment.
That requires defining what counts as "total funds allocated to the SBIR program" (e.g., whether set-aside, agency overhead, or administrative pool monies are included) and coordinating budget, grant, and contract offices. Absent clear regulatory guidance, agencies could take divergent approaches that frustrate cross-agency comparisons and oversight.
Second, expanding the authority to all agencies while retaining an exception for NIH creates distributional pressure. Agencies with different missions and market structures will apply direct-to-Phase II differently; some may use it sparingly, others aggressively.
The reporting requirement under subsection (g)(9) provides a transparency lever, but the bill does not mandate standardized metrics beyond number and dollar value. That limits the ability of Congress or watchdogs to assess whether direct-to-Phase II awards are accelerating commercialization, substituting for Phase I due diligence, or disproportionately favoring certain technology sectors or incumbent awardees.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.